Journal Mobile Options
Table of Contents
Vol. 26, No. 1, 2008
Issue release date: December 2007
Dig Dis 2008;26:40–44

Intragastric Balloon Treatment for Obesity: What Does It Really Offer?

Mathus-Vliegen E.M.H.
Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Obesity is a chronic metabolic disorder with considerable health risks, which can be approved by a sustained modest weight loss. This can be achieved by medical treatment through behavioral therapy, diet, exercise and pharmacotherapy. Surgery is often needed for the severely obese. Intragastric balloon treatment stands in between, being more drastic than medical treatment but less invasive than surgery. In the light of the high premature deflation rate and the high incidence of gastric ulcers, a safer balloon had to be awaited, constructed according to predefined criteria. This new balloon (BioEnterics® Intragastric Balloon™) promoted a weight loss of 5–9 BMI units in 6 months with an impressive improvement of obesity-associated comorbidities. A weight regain of 25–40% has to be considered in a 1-year balloon-free follow-up period. A failure rate of 15% was observed in studies that defined a successful weight loss. With respect to safety, there was no mortality. Gastrointestinal complications, mainly consisting of esophagitis, were present in 5.5%. Intolerance of the balloon resulted in its removal in 7%. Balloons deflated in 8% with an uneventful outcome in all except 5 patients, who had to be operated. Balloon treatment is a valuable method, but nonresponse, intolerance and weight regain have to be taken into account.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. World Health Organization: Obesity: preventing and managing the global epidemic (report of a WHO consultation on obesity). WHO/NUT/NCD/98.1, 1998, pp 1–276.
  2. National Heart, Lung and Blood Institute Education Initiative: Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998;6(suppl 2):108S–209S.
  3. Glenny AM, O’Meara S, Melville A, Sheldon TA, Wilson C: The treatment and prevention of obesity: a systematic review of the literature. Int J Obes 1997;21:715–737.
  4. Schapiro M, Benjamin S, Blackburn G, et al: Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida, March 19–21, 1987. Gastrointest Endosc 1987;33:323–327.
  5. Mathus-Vliegen EMH, Tytgat GNJ: Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span. Br J Surg 1990;77:76–79.
  6. Who needs an intragastric balloon for weight reduction? Lancet 1988;ii:664.
  7. Mathus-Vliegen EMH: Gastric Balloon Revisited. Scientific Sessions Handouts, DDW San Francisco, May 19–22, 2002, pp 212–214.
  8. Mathus-Vliegen EMH: Treating morbid and super-morbid obesity. Int J Gastroenterol 2000;5:9–12.
  9. Gemayel N, Laine L, Cohen H, et al: A prospective, controlled trial of the Garren gastric bubble (GB) with or without 600 calorie diet (D) on weight loss and gastric emptying (abstract). Gut 1987;28:A1412.

    External Resources

  10. Stoltenberg PH, Piziak VK, Dietscher JE: Intragastric balloon treatment of obesity: a randomized double-blind trial (abstract). Gastroenterology 1987;92:1506.
  11. Hogan RB, Johnston JH, Long BW, et al: A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc 1989;35:381–385.
  12. Lindor KD, Hughes RW Jr, Ilstrup DM, et al: Intragastric balloons in comparison with standard therapy for obesity – a randomized, double-blind trial. Mayo Clin Proc 1987;62:992–996.
  13. Meshkinpour H, Hsu D, Farivar S: Effect of gastric bubble as a weight reduction device: a controlled, crossover study. Gastroenterology 1988;95:589–592.
  14. Benjamin SB, Maher KA, Cattau EL Jr, et al: Double-blind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterology 1988;95:581–588.
  15. Levine GM, Goldstein M, Lowe M, et al: The gastric bubble – fad or fantastic? (abstract). Gastroenterology 1987;92:1505.
  16. Ramhamadany E, Owen E, Baird IM: Gastric balloon in obese patients accepted for gastroplasty (abstract). Int J Obes 1988;12:493.

    External Resources

  17. Ramhamadany EM, Fowler J, Baird IM: Effect of the gastric balloon versus sham procedure on weight loss in obese subjects. Gut 1989;30:1054–1057.
  18. Borody T, Carrick J, Brandl S, Cole P: Evaluation of the Danish gastric balloon in the treatment of obesity (abstract). Gastroenterol Soc Aust, Proc, 1987.
  19. Rigaud D, Trostler N, Rozen R, et al: Gastric distension, hunger and energy intake after balloon implantation in severe obesity. Int J Obes Relat Metab Disord 1995;19:489–495.
  20. Mathus-Vliegen EMH, Tytgat GNJ, Veldhuyzen-Offermans EAML: Intragastric balloon in the treatment of super-morbid obesity: double-blind, sham-controlled, cross- over evaluation of 500-milliliter balloon. Gastroenterology1990;99:362–369.
  21. Geliebter A, Melton PM, Gage D, et al: Gastric balloon to treat obesity: a double-blind study in nondieting subjects. Am J Clin Nutr 1990;51:584–588.
  22. Durrans D, Taylor TV: Comparison of weight loss with short-term dietary and intragastric balloon treatment. Gut 1989;30:565–568.
  23. Krakamp B, Leidig P, Gehmlich D, et al: Stomach volume reduction balloon for weight loss: what is the justification for this controversial method? (in German) Zentralbl Chir 1997;122:349–356.
  24. De Goederen-van der Meij S, Pierik RGJM, Oudkerk Pool M, Gouma DJ, Mathus-Vliegen LM: Six months of balloon treatment does not predict the success of gastric banding. Obes Surg 2007;17:88–94.
  25. Hodson RM, Zacharoulis D, Goutzamani E, et al: Management of obesity with the new intragastric balloon. Obes Surg 2001;11:327–329.
  26. Totte E, Hendrickx L, Pauwels M, et al: Weight reduction by means of intragastric device: experience with the Bioenterics intragastric balloon. Obes Surg 2001;11:519–523.
  27. Sallet JA, Marchesini JB, Paiva DS, et al: Brazilian multicenter study of the intragastric balloon. Obes Surg 2004;14:991–998.
  28. Roman S, Napoleon B, Mion F, et al: Intragastric balloon for non-morbid obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg 2004;14:539–544.
  29. Herve J, Wahlen CH, Schaeken A, et al: What becomes of patients one year after the intragastric balloon has been removed? Obes Surg 2005;15:864–870.
  30. Doldi SB, Micheletto G, Di Prisco F, et al: Intragastric balloon in obese patients. Obes Surg 2000;10:578–581.
  31. Evans JD, Scott MH: Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg 2001;88:1245–1248.
  32. Loffredo A, Cappuccio M, De Luca M, et al: Three years experience with the new intragastric balloon, and a preoperative test for success with restrictive surgery. Obes Surg 2001;11:330–333.
  33. Doldi SB, Micheletto G, Perrini M, Librenti MC, Rella S: Treatment of morbid obesity with intragastric balloon (BIB) in association with diet. Obes Surg 2002;12:583–587.
  34. Al-Momen A, El-Mogy I: Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg 2005;15:101–105.
  35. Weiner R, Gutberlet H, Bockhorn H: Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. Obes Surg 1999;9:261–264.
  36. Busetto L, Segato G, De Luca M, et al: Preoperative weight loss by intragastric balloon in superobese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg 2004;14:671–676.
  37. Genco A, Bruni T, Doldi SB, et al: Bioenterics intragastric balloon: the Italian experience with 2515 patients. Obes Surg 2005;15:1161–1164.
  38. Mathus-Vliegen EMH, Tytgat GNJ: Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005;61:19–27.
  39. Genco A, Cipriano M, Bacci V, et al: Bioenterics® intragastric balloon (BIB®): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes 2006;30:129–133.
  40. Vandenplas Y, Bollen P, De Langhe K, Vandemaele K, De Schepper J: Intragastric balloons in adolescents with morbid obesity. Eur J Gastroenterol Hepatol 1999;11:243–245.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50